Rage (Receptor For Advanced Glycation End Products) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
{{#vardefine:wikiId|}}
| Protein Name | RAGE |
|---|
| Gene Symbol | AGER |
|---|
| UniProt ID | Q15120 |
|---|
| PDB Structures | 1DWU, 2B2T, 4O9U |
|---|
| Molecular Weight | ~45 kDa (secreted form) |
|---|
| Subcellular Localization | Cell surface (membrane), cytoplasm, nucleus |
|---|
| Protein Family | Immunoglobulin superfamily |
|---|
| Aliases | AGER, SCARJ1, DAME, Emfor |
|---|
RAGE (Receptor for Advanced Glycation End Products) is a pattern recognition receptor that binds advanced glycation end products (AGEs), damage-associated molecular patterns (DAMPs), and other pro-inflammatory ligands. RAGE plays a critical role in chronic inflammation and oxidative stress that contribute to neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD).
RAGE is a multi-ligand receptor belonging to the immunoglobulin superfamily. It consists of:
- Extracellular domain: One V-type immunoglobulin domain (responsible for ligand binding) and two C-type domains
- Transmembrane domain: Single-pass transmembrane helix
- Intracellular domain: Cytoplasmic tail required for signal transduction
The receptor can exist in multiple isoforms due to alternative splicing, including a soluble form (sRAGE) that acts as a decoy receptor.
In the healthy nervous system, RAGE participates in:
- Development: Neuronal differentiation and migration during embryonic development
- Repair: Tissue repair and regeneration following injury
- Inflammation: Acute inflammatory responses
RAGE expression is normally low in adult brain but becomes upregulated under pathological conditions.
RAGE contributes to AD pathogenesis through multiple mechanisms:
- Aβ Binding: RAGE binds to amyloid-beta (Aβ) peptides, facilitating their transport across the blood-brain barrier and enhancing neuronal uptake
- NF-κB Activation: Ligand binding triggers NF-κB signaling, leading to increased expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
- Oxidative Stress: RAGE activation increases NADPH oxidase activity and ROS production
- Tau Phosphorylation: RAGE-mediated signaling promotes GSK-3β activation and tau hyperphosphorylation
- Synaptic Dysfunction: RAGE-Aβ interactions impair synaptic plasticity and LTP
In PD, RAGE mediates:
- Dopaminergic Neuron Vulnerability: RAGE expression is elevated in substantia nigra of PD patients
- α-Synuclein Aggregation: RAGE can bind α-synuclein and promote its aggregation
- Neuroinflammation: Chronic activation of microglia via RAGE-NF-κB pathway
- Mitochondrial Dysfunction: RAGE signaling impairs mitochondrial complex I activity
- Amyotrophic Lateral Sclerosis (ALS): RAGE contributes to motor neuron injury
- Multiple Sclerosis: RAGE mediates demyelination and axonal loss
- Traumatic Brain Injury: RAGE upregulation exacerbates secondary brain injury
RAGE activates multiple downstream signaling cascades:
flowchart TD
A[RAGE Ligands<br/>AGEs, Aβ, HMGB1] --> B[RAGE Activation] -->
B --> C[NF-κB Pathway] -->
B --> D[MAPK Pathways<br/>ERK, JNK, p38] -->
B --> E[PI3K/Akt Pathway] -->
B --> F[NADPH Oxidase<br/>ROS Generation] -->
C --> G[Pro-inflammatory Cytokines<br/>IL-1β, IL-6, TNF-α] -->
D --> H[Cell Proliferation<br/>Differentiation] -->
E --> I[Cell Survival/Autophagy] -->
F --> J[Oxidative Stress)
G --> K[Chronic Neuroinflammation] -->
J --> L[Oxidative Damage] -->
K --> M[Neurodegeneration] -->
L --> M
Key molecules activated:
- NF-κB: Central transcription factor for inflammatory genes
- MAPK: ERK, JNK, and p38 kinases
- PI3K/Akt: Cell survival pathway
- Rho GTPases: Cytoskeletal dynamics
RAGE represents a therapeutic target for neurodegenerative diseases:
| Strategy |
Compound |
Status |
Notes |
| RAGE inhibitors |
FPS-ZM1 |
Preclinical |
Blocks RAGE-V-type domain |
| Anti-RAGE antibodies |
Various |
Research |
Neutralize RAGE signaling |
| sRAGE mimetics |
Synthetic sRAGE |
Research |
Decoy receptor approach |
| Signal transduction |
Small molecule inhibitors |
Research |
Block downstream pathways |
Other approaches include:
- AGE inhibitors: Prevent AGE formation
- Antioxidants: Reduce oxidative stress
- Anti-inflammatory drugs: Dampen NF-κB activation
Soluble RAGE (sRAGE) levels in cerebrospinal fluid (CSF) and blood are being investigated as:
- Diagnostic biomarkers for AD and PD
- Prognostic markers for disease progression
- Indicators of treatment response
- RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation - Yan et al., JAD 2003
- RAGE in Alzheimer's disease and Parkinson's disease - Srikanth et al., Aging Cell 2011
- RAGE: a receptor for amyloid-beta and its therapeutic potential - Deane et al., JAD 2009
- Soluble RAGE and cognitive decline - Souryal et al., Neurology 2013
- RAGE mediates α-synuclein transport across the blood-brain barrier - Sorrentino et al., Nat Neurosci 2014
Rage (Receptor For Advanced Glycation End Products) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Rage (Receptor For Advanced Glycation End Products) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Search PubMed for latest research on this topic.